FORM 4
[X] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
 OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Lochner Daniel		 2. Issuer Name and Ticker or Trading Symbol

Oyster Point Pharma, Inc. [ OYST ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
Chief Financial Officer
(Last)          (First)          (Middle)

C/O OYSTER POINT PHARMA, INC., 202 CARNEGIE CENTER, SUITE 106		 3. Date of Earliest Transaction (MM/DD/YYYY)

1/29/2022
(Street)

PRINCETON, NJ 08540
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
 6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 1/29/2022  F(1)  938 D$11.70 76525 (2)D  
Common Stock 1/3/2023  U  56289 D (3)(4)20236 D  
Common Stock 1/3/2023  D  20236 (5)D (5)0 D  

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)		2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)		8. Price of Derivative Security
(Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Performance Stock Units  (6)1/3/2023  D     300000   (7)7/5/2032 Common Stock 300000  (7)0 D  
Stock Option (Right to Buy) $11.51 1/3/2023  D     161251   (8)(9)7/25/2029 Common Stock 161251  (10)0 D  
Stock Option (Right to Buy) $32.65 1/3/2023  D     72648   (8)(9)2/3/2030 Common Stock 72648  (10)0 D  
Stock Option (Right to Buy) $18.77 1/3/2023  D     50500   (8)(9)1/29/2031 Common Stock 50500  (10)0 D  
Stock Option (Right to Buy) $13.78 1/3/2023  D     45000   (8)(9)8/26/2031 Common Stock 45000  (10)0 D  
Stock Option (Right to Buy) $16.00 1/3/2023  D     87900   (8)(9)1/9/2032 Common Stock 87900  (10)0 D  
Explanation of Responses:
(1) The transaction reported represents the withholding of shares by the Issuer on January 29, 2022 to satisfy the Reporting Person's tax withholding obligations in connection with the non-reportable vesting and settlement of restricted stock units. This transaction is being reported late due to an inadvertent administrative error.
(2) Includes an aggregate of 3,000 shares acquired under the Issuer's Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).
(3) Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated November 7, 2022, among the Issuer, Iris Purchaser Inc. ("Purchaser"), a wholly owned subsidiary of Viatris, Inc. ("Viatris"), and Viatris, Purchaser commenced a tender offer (the "Offer") to purchase all the outstanding common stock of the Issuer for the Per Share Price (as defined below). On January 3, 2023, the Offer was consummated, after which Purchaser merged with and into the Issuer with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Viatris (the "Merger"). At the consummation of the Offer and the Merger, respectively, (i) Purchaser purchased all shares of Issuer's common stock that were validly tendered pursuant to the Offer for a cash payment equal to the Per Share Price and (ii) each share of the Issuer's common stock that was issued and outstanding immediately prior to the effective time of the Merger (the "Effective Time")(continued in Footnote 4)
(4) (other than shares that were held (a) by the Issuer (including any treasury shares) or by Viatris or Purchaser or any other direct or indirect wholly owned subsidiary of Viatris or (b) by stockholders of the Issuer who had properly exercised and perfected, and not withdrawn or otherwise lost, their appraisal rights under the Delaware General Corporate Law) was cancelled and converted into the right to receive (a) a cash payment of $11.00 per share (the "Cash Amount") and (b) one non-transferable contractual contingent value right representing the right to receive any applicable milestone payment if specified milestones are achieved (the "Milestone Payment" and together with the Cash Amount, the "Per Share Price") pursuant to a Contingent Value Rights Agreement, dated January 3, 2023, by and between Viatris and American Stock Transfer & Trust Company, LLC as Rights Agent.
(5) This line item represents unvested restricted stock units with respect to the Issuer's common stock ("RSUs") held by the Reporting Person. Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unvested RSU or portion thereof was converted into a restricted stock unit with respect to Viatris common stock (rounded down to the nearest whole share) determined by multiplying the total number of shares deliverable under such RSUs as of immediately prior to the Effective Time and the Equity Award Exchange Ratio (as defined in the Merger Agreement), subject to substantially the same terms and conditions, including vesting conditions, as were applicable to such RSUs immediately prior to the Effective Time.
(6) This line item represents performance stock units ("PSUs") held by the Reporting Person. Each PSU represents a contingent right to receive one share of common stock of the Issuer.
(7) Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unvested PSU was converted into a time-based vesting restricted stock unit with respect to Viatris common stock (rounded down to the nearest whole share) determined by multiplying the target number of shares deliverable under such PSUs as of immediately prior to the Effective Time and the Equity Award Exchange Ratio (as defined in the Merger Agreement), subject to substantially the same terms and conditions, including vesting conditions, as were applicable to such PSUs immediately prior to the Effective Time.
(8) This line item represents stock options held by the Reporting Person. Pursuant to the Merger Agreement, at the Effective Time, each outstanding vested stock option with an exercise price less than $13.00 was canceled and converted into the right to receive an amount in cash, equal to the excess, if any, of the Per Share Price over the exercise price applicable to such stock option, less applicable tax withholdings.
(9) In addition, pursuant to the Merger Agreement, at the Effective Time, each outstanding, unvested and unexercised stock option with an exercise price less than $13.00 will be converted into an option to purchase a number of shares of Viatris common stock (rounded down to the nearest whole share) determined by multiplying the number of shares deliverable under such stock option as of immediately prior to the Effective Time and the Equity Award Exchange Ratio (as defined in the Merger Agreement), and with an exercise price per share that is equal to the quotient (rounded up to the nearest cent) of the exercise price per share of such stock option as of immediately prior to the Effective Time divided by the Equity Award Exchange Ratio, subject to substantially the same terms and conditions, including vesting conditions, as were applicable to such stock option immediately prior to the Effective Time.
(10) Each vested and unvested stock option that has an exercise price per share that is equal to or greater than the Per Share Price will be canceled for no consideration.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Lochner Daniel
C/O OYSTER POINT PHARMA, INC.
202 CARNEGIE CENTER, SUITE 106
PRINCETON, NJ 08540

Chief Financial Officer
Signatures
/s/ Brandon Fenn, Attorney-in-Fact1/4/2023
**Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Oyster Point Pharma (NASDAQ:OYST)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Oyster Point Pharma Charts.
Oyster Point Pharma (NASDAQ:OYST)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Oyster Point Pharma Charts.